ATE404564T1 - Diazepinoindolderivate als kinaseinhibitoren - Google Patents

Diazepinoindolderivate als kinaseinhibitoren

Info

Publication number
ATE404564T1
ATE404564T1 AT04700145T AT04700145T ATE404564T1 AT E404564 T1 ATE404564 T1 AT E404564T1 AT 04700145 T AT04700145 T AT 04700145T AT 04700145 T AT04700145 T AT 04700145T AT E404564 T1 ATE404564 T1 AT E404564T1
Authority
AT
Austria
Prior art keywords
diazepinoindol
derivatives
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
AT04700145T
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael Bennett
Yuanjin Eugene Rui
Fen Wang
Suzanne BENEDICT
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE404564T1 publication Critical patent/ATE404564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04700145T 2003-01-09 2004-01-05 Diazepinoindolderivate als kinaseinhibitoren ATE404564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
ATE404564T1 true ATE404564T1 (de) 2008-08-15

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04700145T ATE404564T1 (de) 2003-01-09 2004-01-05 Diazepinoindolderivate als kinaseinhibitoren

Country Status (34)

Country Link
US (3) US6967198B2 (de)
EP (2) EP1947102A1 (de)
JP (1) JP3990718B2 (de)
KR (1) KR100697746B1 (de)
CN (1) CN1759118B (de)
AP (1) AP2048A (de)
AT (1) ATE404564T1 (de)
AU (1) AU2004203977B2 (de)
BR (1) BRPI0406701A (de)
CA (1) CA2512683C (de)
CR (1) CR7899A (de)
CY (1) CY1108408T1 (de)
DE (1) DE602004015724D1 (de)
DK (1) DK1585749T3 (de)
EA (1) EA009337B1 (de)
EC (1) ECSP055911A (de)
ES (1) ES2309484T3 (de)
GE (1) GEP20084367B (de)
HR (1) HRP20050624A2 (de)
IL (1) IL169082A (de)
IS (1) IS7884A (de)
MA (1) MA27703A1 (de)
MX (1) MXPA05007352A (de)
NO (1) NO20053775L (de)
NZ (1) NZ540638A (de)
OA (1) OA13017A (de)
PL (1) PL378372A1 (de)
PT (1) PT1585749E (de)
RS (1) RS20050522A (de)
SI (1) SI1585749T1 (de)
TN (1) TNSN05176A1 (de)
UA (1) UA80733C2 (de)
WO (1) WO2004063198A1 (de)
ZA (1) ZA200504674B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2512683C (en) * 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
US20080145358A1 (en) * 2005-02-18 2008-06-19 Astrazeneca Ab Method for Determining Responsiveness to Chk1 Inhibitors
EP2330105A1 (de) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl substituierte Harnstoffe als CHK1-Inhibitoren
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2389532T3 (es) 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
EP1928907A4 (de) 2005-08-15 2009-03-11 Univ California Vegf-aktivierte fas-liganden
EP1942193A4 (de) 2005-08-25 2010-10-27 Ube Industries VERFAHREN ZUR HERSTELLUNG OPTISCH AKTIVER (S ODER R)-a- AMINOSÄURE ODER EINES OPTISCH AKTIVEN (S ODER R) -a-AMINOSÄUREESTERS
WO2007025303A2 (en) * 2005-08-26 2007-03-01 The Regents Of The University Of California Non-steroidal antiandrogens
WO2007113647A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
RU2409361C2 (ru) * 2006-04-04 2011-01-20 Пфайзер Продактс Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ
CA2669982A1 (en) * 2006-11-17 2008-05-29 Schering Corporation Combination therapy for proliferative disorders
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ATE542813T1 (de) * 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
EP2346881A1 (de) * 2008-10-10 2011-07-27 Priaxon AG Neue verbindungen, die die kinaseaktivität modulieren
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
DK2797921T3 (en) 2011-12-31 2017-10-02 Beigene Ltd FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
EP2797919B1 (de) 2011-12-31 2017-03-29 BeiGene, Ltd. Kondensierte tetra- oder penta-cyclische pyridophthalazinone als parp-inhibitoren
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
NZ739876A (en) 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
WO2019058393A1 (en) * 2017-09-22 2019-03-28 Jubilant Biosys Limited HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD
EP3461480A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
JP2022523028A (ja) * 2019-01-25 2022-04-21 ヌメディー， インコーポレイテッド 特発性肺線維症を処置するための方法
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
ES3014705T3 (en) 2019-11-29 2025-04-24 Novaonco Js Therapeutics Co Ltd Diazaindole derivative and use thereof as chk1 inhibitor
US20230330244A1 (en) * 2020-07-13 2023-10-19 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
EP4190790A1 (de) * 2020-07-31 2023-06-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indoloheptamyloxim-analog-kristall als parp-hemmer und verfahren zur herstellung davon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
WO2000016781A1 (en) 1998-09-18 2000-03-30 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
ES2302699T3 (es) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
ES2354249T3 (es) * 2000-12-01 2011-03-11 Eisai Inc. Derivados de azafenantridona y su uso como inhibidores de parp.
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
CA2512683C (en) * 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Also Published As

Publication number Publication date
US20070135415A1 (en) 2007-06-14
KR100697746B1 (ko) 2007-03-22
SI1585749T1 (sl) 2008-10-31
US20060004052A1 (en) 2006-01-05
CN1759118A (zh) 2006-04-12
PT1585749E (pt) 2008-10-23
US20050075499A1 (en) 2005-04-07
IL169082A (en) 2011-02-28
CN1759118B (zh) 2010-12-08
NO20053775L (no) 2005-09-16
MA27703A1 (fr) 2006-01-02
MXPA05007352A (es) 2006-02-17
PL378372A1 (pl) 2006-04-03
AP2005003353A0 (en) 2005-09-30
CR7899A (es) 2005-08-05
JP2006516274A (ja) 2006-06-29
NO20053775D0 (no) 2005-08-08
CA2512683C (en) 2010-03-16
EP1585749B1 (de) 2008-08-13
WO2004063198A1 (en) 2004-07-29
JP3990718B2 (ja) 2007-10-17
AP2048A (en) 2009-09-24
EA009337B1 (ru) 2007-12-28
US7462713B2 (en) 2008-12-09
DE602004015724D1 (de) 2008-09-25
CY1108408T1 (el) 2014-02-12
AU2004203977B2 (en) 2010-06-17
NZ540638A (en) 2007-12-21
KR20050092397A (ko) 2005-09-21
OA13017A (en) 2006-11-10
AU2004203977A1 (en) 2004-07-29
EP1585749A1 (de) 2005-10-19
US7132533B2 (en) 2006-11-07
EP1947102A1 (de) 2008-07-23
UA80733C2 (en) 2007-10-25
ECSP055911A (es) 2005-11-22
CA2512683A1 (en) 2004-07-29
ES2309484T3 (es) 2008-12-16
DK1585749T3 (da) 2008-09-22
GEP20084367B (en) 2008-05-13
US6967198B2 (en) 2005-11-22
IS7884A (is) 2005-06-09
ZA200504674B (en) 2006-07-26
RS20050522A (sr) 2007-12-31
EA200500893A1 (ru) 2006-02-24
HRP20050624A2 (en) 2006-02-28
TNSN05176A1 (fr) 2007-06-11
HK1086257A1 (en) 2006-09-15
BRPI0406701A (pt) 2005-12-20

Similar Documents

Publication Publication Date Title
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE388148T1 (de) Chinolinderivate als phosphodiesterase inhibitoren
IS7599A (is) Heterósýklískir kínasatálmar
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1585749

Country of ref document: EP

REN Ceased due to non-payment of the annual fee